E7P Stock Chart & Stats
€27.60
--
Market closed
€27.60
--
Day’s Range― - ―
52-Week Range€17.50 - €36.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)12.00
Market Cap
€3.63B
Enterprise Value€5.37K
Total Cash (Recent Filing)€222.00M
Total Debt (Recent Filing)€509.00M
Price to Earnings (P/E)12.4
Beta0.02
Next Earnings
Oct 29, 2026EPS Estimate
0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.84
Shares Outstanding118,013,650
10 Day Avg. Volume5
30 Day Avg. Volume12
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-45.77
Price to Sales (P/S)3.62
P/FCF Ratio-47.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€41.13Price Target Upside49.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)3.5
Revenue Forecast (FY)€1.13B
Bulls Say, Bears Say
Bulls Say
SUBLOCADE-led Revenue GrowthStrong SUBLOCADE growth and higher first-half revenue indicate sustained demand for Indivior’s core OUD franchise. Continued volume expansion can support operating leverage and improve the company’s earnings profile over the next several quarters.
Durable SUBLOCADE Competitive PositionHigh market share, record patient starts, manufacturing complexity, and long-dated patent protection create meaningful barriers to generic and branded competition. These advantages support durable product economics while long-acting injectable adoption remains underpenetrated.
Merger Scale And Cost SynergiesThe merger broadens Indivior’s CNS portfolio and commercial infrastructure while offering tangible cost savings within 12 months. Greater scale and a diversified set of growth products could strengthen margins, cash generation, and business development capacity.
Bears Say
Negative And Volatile Cash GenerationWeak cash conversion reduces the reliability of reported earnings and may require greater reliance on balance-sheet resources to fund operations, investment, or transactions. Repeated negative cash flow also limits flexibility if product growth or working capital deteriorates.
Persistently Negative Shareholders’ EquityAn equity deficit leaves less capital protection against operating setbacks and makes the balance sheet less resilient in a downturn. Low reported debt does not fully offset this structural weakness, particularly as the company pursues a major transaction.
SUBLOCADE Concentration And Merger Execution RiskHeavy dependence on one product makes revenue vulnerable to payer changes, competition, or slower long-acting injectable adoption. At the same time, combining two organizations could disrupt commercial momentum or delay the planned synergies if approvals and integration are not executed well.
Indivior News
E7P FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was €17.50 and its highest was €36.20 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is €3.63B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Aug 03, 2026. The company reported €0.997 earnings per share for the quarter, beating the consensus estimate of €0.753 by €0.244.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 0.92.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 118,013,650 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of €0.997 in its last earnings report, beating expectations of €0.753. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in DE:E7P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Indivior Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€41.13 (49.03% Upside)
€41.13 (49.03% Upside)
Blogger Sentiment
Bullish
DE:E7P Sentiment 83%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €92.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.08%
Trailing 12-Months
Company Description
Indivior PLC
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
E7P Company Deck
E7P Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presents a constructive and optimistic view of the merger: management emphasized scale, a diversified portfolio (~$2.2B pro forma revenue), strong pro forma profitability (adjusted EBITDA $888M; ~41% margin), and $125M of near-term cost synergies, while retaining balance sheet strength and highlighting SUBLOCADE as a durable, large growth driver (~44% of revenue) supported by IP and commercial momentum. Noted risks include revenue concentration in SUBLOCADE, increased pro forma net debt (~$878M, ~1x leverage), absence of quantified revenue synergies, and standard integration and regulatory execution risks. On balance, the positives (scale, margins, synergies, product durability) outweigh the lowlights.View all DE:E7P earnings summariesE7P Stock 12 Month Forecast
Average Price Target
€41.13
▲(49.03% Upside)
Technical Analysis
Neurocrine
―
Supernus Pharmaceuticals
―
Teva Pharmaceutical
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―